Humanized Mouse Models of Clinical Disease

Annual Review of Pathology: Mechanisms of Disease

Volumn 12, Issue , 2017, Pages 187-215

  Walsh, Nicole C ^a   Kenney, Laurie L ^a   Jangalwe, Sonal ^a   Aryee, Ken Edwin ^a   Greiner, Dale L ^a   Brehm, Michael A ^a   Shultz, Leonard D ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

Allergy; Autoimmunity; Cancer; Humanized mice; Immunodeficient mice; Infectious disease; Regenerative medicine

Indexed keywords

ALLOGRAFT; ANAPHYLAXIS; ARTHRITIS; ATOPIC DERMATITIS; AUTOIMMUNITY; CANCER IMMUNOLOGY; CHRONIC INFLAMMATION; DELTA AGENT HEPATITIS; DENGUE; EBOLAVIRUS; EPSTEIN BARR VIRUS INFECTION; HANTAVIRUS INFECTION; HEPATITIS B; HEPATITIS C; HEPATITIS E; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOTHERAPY; INFECTION; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; KAPOSI SARCOMA; LIVER DISEASE; MALARIA; MEDICAL RESEARCH; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TUBERCULOSIS; TUMOR GROWTH; TUMOR XENOGRAFT; TYPHOID FEVER; ULCERATIVE COLITIS; VASCULITIS; VIROLOGY; ANIMAL; COMMUNICABLE DISEASES; DISEASE MODEL; IMMUNE SYSTEM; IMMUNOLOGY; SCID MOUSE;

ANIMALS; COMMUNICABLE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; MICE; MICE, SCID;

EID: 85011263122     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-052016-100332     Document Type: Review

References (155)

1. Zschaler J, Schlorke D, Arnhold J. 2014. Differences in innate immune response between man and mouse. Crit. Rev. Immunol. 34:433-54
2. Ai M, Curran MA. 2015. Immune checkpoint combinations from mouse to man. Cancer Immunol. Immunother. 64:885-92
3. Brehm MA, Bortell R, Verma M, Shultz LD, Greiner DL. 2016. Humanized mice in translational immunology. In Translational Immunology: Mechanisms and Pharmacological Approaches, ed. S-L Tan, pp. 285-326. Boston: Academic
4. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. 2012. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12:786-98
5. Shultz LD, Ishikawa F, Greiner DL. 2007. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7:118-30
6. Theocharides AP, Rongvaux A, Fritsch K, Flavell RA, Manz MG. 2016. Humanized hemato-lymphoid system mice. Haematologica 101:5-19
7. Akkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, et al. 2016. Improvements and limitations of humanized mouse models for HIV research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary. AIDS Res. Hum. Retrovir. 32:109-19
8. King MA, Covassin L, Brehm MA, Racki W, Pearson T, et al. 2009. Hu-PBL-NOD-scid IL2rgnull mousemodel of xenogeneic graft-versus-host-like disease and the role of host MHC. Clin. Exp. Immunol. 157:104-18
9. Watanabe Y, Takahashi T, Okajima A, Shiokawa M, Ishii N, et al. 2009. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/γcnull (NOG) mice (hu-HSC NOG mice). Int. Immunol. 21:843-58
10. Halkias J, Yen B, Taylor KT, Reinhartz O,Winoto A, et al. 2015. Conserved and divergent aspects of human T-cell development and migration in humanized mice. Immunol. Cell Biol. 93:716-26
11. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, et al. 2006. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12:1316-22
12. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. 2006. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108:487-92
13. Policicchio BB, Pandrea I, Apetrei C. 2016. Animal models for HIV cure research. Front. Immunol. 7:12
14. Denton PW, Sogaard OS, Tolstrup M. 2016. Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. J. Transl. Med. 14:44
15. Veselinovic M, Charlins P, Akkina R. 2016. Modeling HIV-1 mucosal transmission and prevention in humanized mice. Methods Mol. Biol. 1354:203-20
16. Gaska JM, Ploss A. 2015. Study of viral pathogenesis in humanized mice. Curr. Opin. Virol. 11:14-20
17. Karpel ME, Boutwell CL, Allen TM. 2015. BLT humanized mice as a small animal model of HIV infection. Curr. Opin. Virol. 13:75-80
18. Yamada E, Yoshikawa R,Nakano Y,MisawaN, Koyanagi Y, Sato K. 2015. Impacts of humanizedmouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivo. Viruses 7:1373-90
19. Akkina R. 2013. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435:14-28
20. Choudhary SK, Archin NM, CheemaM,DahlNP, Garcia JV,Margolis DM. 2012. LatentHIV-1 infection of resting CD4+ T cells in the humanized Rag2-/-γc-/-mouse. J. Virol. 86:114-20
21. Honeycutt JB, Wahl A, Archin N, Choudhary S, Margolis D, Garcia JV. 2013. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology 10:121
22. Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, et al. 2012. HIV latency in the humanized BLT mouse. J. Virol. 86:339-47
23. Honeycutt JB, Sheridan PA, Matsushima GK, Garcia JV. 2015. Humanized mouse models for HIV-1 infection of the CNS. J. Neurovirol. 21:301-9
24. Olesen R, SwansonMD, Kovarova M, NochiT,Chateau M, et al. 2016.ARTinfluencesHIV persistence in the female reproductive tract and cervicovaginal secretions. J. Clin. Investig. 126:892
25. Sewald X, Ladinsky MS, Uchil PD, Beloor J, Pi R, et al. 2015. Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science 350:563-67
26. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365:493-505
27. Holt N, Wang J, Kim K, Friedman G, Wang X, et al. 2010. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28:839-47
28. Myburgh R, Ivic S, Pepper MS, Gers-Huber G, Li D, et al. 2015. Lentivector knockdown of CCR5 in hematopoietic stem and progenitor cells confers functional and persistent HIV-1 resistance in humanized mice. J. Virol. 89:6761-72
29. Kordelas L, Verheyen J, Beelen DW,Horn PA, Heinold A, et al. 2014. Shift of HIV tropism in stem-cell transplantation with CCR5 32 mutation. N. Engl. J. Med. 371:880-82
30. Burke BP, Levin BR, Zhang J, Sahakyan A, Boyer J, et al. 2015. Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol. Ther. Nucleic Acids 4:e236
31. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, et al. 2014. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-99
32. Hur EM, Patel SN, Shimizu S, Rao DS, Gnanapragasam PN, et al. 2012. Inhibitory effect of HIVspecific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 120:4571-82
33. Palmer BE,Neff CP, Lecureux J, Ehler A, DsouzaM, et al. 2013. In vivo blockade of the PD-1 receptor suppressesHIV-1 viral loads and improves CD4+ T cell levels in humanizedmice. J. Immunol. 190:211-19
34. SeungE,DudekTE, AllenTM, Freeman GJ, Luster AD, TagerAM. 2013. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLOS ONE 8:e77780
35. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81-84
36. Cox J,Mota J, Sukupolvi-Petty S, DiamondMS, Rico-Hesse R. 2012. Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J. Virol. 86:7637-49
37. Frias-Staheli N, Dorner M, Marukian S, Billerbeck E, Labitt RN, et al. 2014. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J. Virol. 88:2205-18
38. Jaiswal S, Pazoles P, Woda M, Shultz LD, Greiner DL, et al. 2012. Enhanced humoral and HLA-A2-restricted dengue virus-specificT-cell responses in humanized BLTNSGmice. Immunology 136:334-43
39. Jaiswal S, Pearson T, Friberg H, Shultz LD, Greiner DL, et al. 2009. Dengue virus infection and virusspecific HLA-A2 restricted immune responses in humanized NOD-scid IL2rγnull mice. PLOS ONE 4:e7251
40. Jaiswal S, Smith K, Ramirez A,Woda M, Pazoles P, et al. 2015. Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp. Biol. Med. 240:67-78
41. Kuruvilla JG, Troyer RM, Devi S, Akkina R. 2007. Dengue virus infection and immune response in humanized RAG2-/-γc-/-(RAG-hu) mice. Virology 369:143-52
42. McCarthy M. 2016. WHO sets out $56m Zika virus response plan. BMJ 352:i1042
43. Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. 2015. The immunology of Epstein-Barr virus-induced disease. Annu. Rev. Immunol. 33:787-821
44. Fujiwara S, Imadome K, Takei M. 2015. Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp. Mol. Med. 47:e135
45. Gujer C, Chatterjee B, Landtwing V, Raykova A, McHugh D, Munz C. 2015. Animal models of Epstein Barr virus infection. Curr. Opin. Virol. 13:6-10
46. Strowig T,Gurer C, Ploss A, Liu YF, Arrey F, et al. 2009. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206:1423-34
47. Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, et al. 2010. Generation of functional human Tcell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnull humanized mice. PNAS 107:13022-27
48. Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, et al. 2013. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 5:1489-98
49. Yu CI, Becker C, Wang Y, Marches F, Helft J, et al. 2013. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effectorTcells via the cytokine TGF-and beta;. Immunity 38:818-30
50. Willinger T, Rongvaux A, Takizawa H, Yancopoulos GD, Valenzuela DM, et al. 2011. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. PNAS 108:2390-95
51. Li Y, Chen Q, Zheng D, Yin L, Chionh YH, et al. 2013. Induction of functional human macrophages from bone marrow promonocytes by M-CSF in humanized mice. J. Immunol. 191:3192-99
52. Wang LX, Kang G, Kumar P, Lu W, Li Y, et al. 2014. Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection. PNAS 111:3146-51
53. Libby SJ, Brehm MA, Greiner DL, Shultz LD, McClelland M, et al. 2010. Humanized nonobese diabetic-scid IL2rγnull mice are susceptible to lethal Salmonella Typhi infection. PNAS 107:15589-94
54. Firoz MM, Pek EA, Chenoweth MJ, Ashkar AA. 2011. Humanized mice are susceptible to Salmonella typhi infection. Cell Mol. Immunol. 8:83-87
55. Song J, Willinger T, Rongvaux A, Eynon EE, Stevens S, et al. 2010. A mouse model for the human pathogen Salmonella Typhi. Cell Host. Microbe 8:369-76
56. Heuts F,Gavier-Widen D, Carow B, Juarez J, WigzellH, RottenbergME. 2013. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. PNAS 110:6482-87
57. Calderon VE, Valbuena G, Goez Y, Judy BM, Huante MB, et al. 2013. A humanized mouse model of tuberculosis. PLOS ONE 8:e63331
58. Lee J, Brehm MA, Greiner D, Shultz LD, Kornfeld H. 2013. Engrafted human cells generate adaptive immune responses to Mycobacterium bovis BCG infection in humanized mice. BMC Immunol. 14:53
59. Ludtke A, Oestereich L, Ruibal P, Wurr S, Pallasch E, et al. 2015. Ebola virus disease in mice with transplanted human hematopoietic stem cells. J. Virol. 89:4700-4
60. Bird BH, Spengler JR, Chakrabarti AK, KhristovaML, Sealy TK, et al. 2015. Humanized mouse model of ebola virus disease mimics the immune responses in human disease. J. Infect. Dis. 213:703-11
61. Kobak L, Raftery MJ, Voigt S, Kuhl AA, Kilic E, et al. 2015. Hantavirus-induced pathogenesis in mice with a humanized immune system. J. Gen. Virol. 96:1258-63
62. Siu E, Ploss A. 2015. Modeling malaria in humanized mice: opportunities and challenges. Ann. N.Y. Acad. Sci. 1342:29-36
63. Good MF, Hawkes MT, Yanow SK. 2015. Humanized mouse models to study cell-mediated immune responses to liver-stage malaria vaccines. Trends Parasitol. 31:583-94
64. Jimenez-Diaz MB, Mulet T, Viera S, Gomez V, Garuti H, et al. 2009. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rγ null mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53:4533-36
65. Soulard V, Bosson-Vanga H, Lorthiois A, Roucher C, Franetich JF, et al. 2015. Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice. Nat. Commun. 6:7690
66. VaughanAM,Mikolajczak SA,WilsonEM,GrompeM, KaushanskyA, et al. 2012. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J. Clin. Investig 122:3618-28
67. Vaughan AM, Pinapati RS, Cheeseman IH, Camargo N, Fishbaugher M, et al. 2015. Plasmodium falciparum genetic crosses in a humanized mouse model. Nat. Methods 12:631-33
68. Foquet L, Meuleman P, Hermsen CC, Sauerwein R, Leroux-Roels G. 2015. Assessment of parasite liver-stage burden in human-liver chimeric mice. Methods Mol. Biol. 1325:59-68
69. Ernst W, Zimara N, Hanses F, Mannel DN, Seelbach-Gobel B, Wege AK. 2013. Humanized mice, a new model to study the influence of drug treatment on neonatal sepsis. Infect. Immun. 81:1520-31
70. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. 2009. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J. Leukoc. Biol. 86:219-27
71. Skirecki T, Kawiak J, Machaj E, Pojda Z, Wasilewska D, et al. 2015. Early severe impairment of hematopoietic stem and progenitor cells from the bone marrow caused by CLP sepsis and endotoxemia in a humanized mice model. Stem Cell Res. Ther. 6:142
72. Ye C, Choi JG, Abraham S,Wu H, Diaz D, et al. 2012. Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. PNAS 109:21052-57
73. ChengL,LiF,BilityMT, MurphyCM,SuL. 2015. Modeling hepatitisBvirus infection, immunopathology and therapy in mice. Antiviral Res. 121:1-8
74. von SM, Ding Q, Ploss A. 2014. Visualizing hepatitis C virus infection in humanized mice. J. Immunol. Methods 410:50-59
75. Li S, Ling C, Zhong L, LiM, SuQ, et al. 2015. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23:1867-76
76. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, et al. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:927-33
77. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, et al. 2010. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Investig. 120:924-30
78. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, et al. 2011. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 140:1334-44
79. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, et al. 2015. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat. Biotechnol. 33:549-54
80. Vercauteren K, Van den Eede N, Mesalam AA, Belouzard S, Catanese MT, et al. 2014. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 60:1508-18
81. de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, et al. 2014. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci. Transl. Med. 6:254ra129
82. Wang Z, Wu N, Tesfaye A, Feinstone S, Kumar A. 2015. HCV infection-associated hepatocellular carcinoma in humanized mice. Infect. Agent. Cancer 10:24
83. Allweiss L, Volz T, Lutgehetmann M, Giersch K, Bornscheuer T, et al. 2014. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-α administration. J. Hepatol. 60:500-7
84. Bility MT, Cheng L, Zhang Z, Luan Y, Li F, et al. 2014. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLOS Pathog. 10:e1004032
85. Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, et al. 2015. Hepatitis delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV monoinfection. J. Hepatol. 63:346-53
86. Allweiss L, Gass S, Giersch K, Groth A, Kah J, et al. 2016. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. J. Hepatol. 64:1033-40
87. Zhang RR, Zheng YW, Li B, Tsuchida T, Ueno Y, et al. 2015. Human hepatic stem cells transplanted into a fulminant hepatic failure Alb-TRECK/SCID mouse model exhibit liver reconstitution and drug metabolism capabilities. Stem Cell Res. Ther. 6:49
88. Xu D, Michie SA, Zheng M, Takeda S,WuM, PeltzG. 2015. Humanized thymidine kinase-NOG mice can be used to identify drugs that cause animal-specific hepatotoxicity: a case study with furosemide. J. Pharmacol. Exp. Ther. 354:73-78
89. Xu D,WuM, Nishimura S,Nishimura T, Michie SA, et al. 2015. Chimeric TK-NOGmice: a predictive model for cholestatic human liver toxicity. J. Pharmacol. Exp. Ther. 352:274-80
90. Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. 2014. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb. Protoc. 2014:694-708
91. Cassidy JW, Caldas C, Bruna A. 2015. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 75:2963-68
92. Shankavaram UT, Bredel M, Burgan WE, Carter D, Tofilon P, Camphausen K. 2012. Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. J. Cell Mol. Med. 16:545-54
93. Rosfjord E, Lucas J, Li G, Gerber HP. 2014. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem. Pharmacol. 91:135-43
94. Maykel J, Liu JH, Li H, Shultz LD, Greiner DL, Houghton J. 2014. NOD-scidIl2rgtm1Wjl and NODRag1nullIl2rgtm1Wjl: a model for stromal cell-tumor cell interaction for human colon cancer. Dig. Dis. Sci. 59:1169-79
95. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, et al. 2011. Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy. Int. J. Cancer 129:2194-206
96. Roth MD,Harui A. 2015. Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J. Immunother. Cancer 3:12
97. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, et al. 2014. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32:364-72
98. Rezvani K, Rouce RH. 2015. The application of natural killer cell immunotherapy for the treatment of cancer. Front. Immunol. 6:578
99. Liu D, Song L,Wei J, Courtney AN, Gao X, et al. 2012. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J. Clin. Investig. 122:2221-33
100. Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, et al. 2013. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rgnull mice. PLOS ONE 8:e64384
101. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, et al. 2010. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9053-61
102. Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, et al. 2015. Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction andmyogenic differentiation. Oncoimmunology 4:e1014760
103. Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, et al. 2016. XactMice:Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 35:290-300
104. Varga J, Lopatin M, Boden G. 1990. Hypoglycemia due to antiinsulin receptor antibodies in systemic lupus erythematosus. J. Rheumatol. 17:1226-29
105. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8:299-308
106. Provasi E, Genovese P, Lombardo A,Magnani Z, Liu PQ, et al. 2012. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18:807-15
107. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, et al. 2013. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19:3153-64
108. Casucci M, Nicolis Robilant B, Falcone L, Camisa B, Norelli M, et al. 2013. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122:3461-72
109. Song DG, Powell DJ. 2012. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. Oncoimmunology 1:547-49
110. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, et al. 2014. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124:1070-80
111. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. 2013. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31:71-75
112. Deleted in proof
113. Chu Y, Hochberg J, Yahr A, Ayello J, Ven C, et al. 2014. Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol. Res. 3:333-44
114. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, et al. 2012. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72:1844-52
115. Horvath C, Andrews L, Baumann A, Black L, Blanset D, et al. 2012. Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nat. Rev. Immunol. 12:740
116. Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, et al. 2016. Induction of WT1-specific human CD8+ T cells from humanHSCs in HLA class I Tg NOD/SCID/IL2rγKO mice. Blood 127:722-34
117. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, et al. 2012. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol. Immunother. 61:1721-33
118. Mullard A. 2013. New checkpoint inhibitors ride the immunotherapy tsunami. Nat. Rev. Drug Discov. 12:489-92
119. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134-44
120. Sanmamed MF,Rodriguez I, Schalper KA,Onate C, Azpilikueta A, et al. 2015. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice. Cancer Res. 75:3466-78
121. Brady JL, Harrison LC, Goodman DJ, Cowan PJ,Hawthorne WJ, et al. 2014. Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model. Clin. Transl. Immunol. 3:e29
122. Weissmuller S, Kronhart S, Kreuz D, Schnierle B, Kalinke U, et al. 2016. TGN1412 induces lymphopenia and human cytokine release in a humanized mousemodel. PLOSONE11:e0149093
123. Brehm MA, Shultz LD. 2012. Human allograft rejection in humanized mice: a historical perspective. Cell Mol. Immunol. 9:225-31
124. Hogenes M, Huibers M, Kroone C, de Weger R. 2014. Humanized mouse models in transplantation research. Transplant. Rev. 28:103-10
125. Kenney LL, Shultz LD, Greiner DL, Brehm MA. 2016. Humanized mouse models for transplant immunology. Am. J. Transplant. 16:389-97
126. Jacobson S, Heuts F, Juarez J, HultcrantzM, Korsgren O, et al. 2010. Alloreactivity but failure to reject human islet transplants by humanized Balb/c/Rag2-/-gc-/-mice. Scand. J. Immunol. 71:83-90
127. Brehm MA, Bortell R, DiIorio P, Leif J, Laning J, et al. 2010. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rγ null Ins2Akita mice. Diabetes 59:2265-70
128. Xiao F, Ma L, Zhao M, Huang G, Mirenda V, et al. 2014. Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rγnull mice. PLOS ONE 9:e90387
129. Kirkiles-SmithNC, HardingMJ, ShepherdBR, Fader SA, Yi T, et al. 2009. Development of a humanized mouse model to study the role of macrophages in allograft injury. Transplantation 87:189-97
130. Viehmann Milam AA, Maher SE, Gibson JA, Lebastchi J, Wen L, et al. 2014. A humanized mouse model of autoimmune insulitis. Diabetes 63:1712-24
131. Babad J, Mukherjee G, Follenzi A, Ali R, Roep BO, et al. 2015. Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice. Clin. Exp. Immunol. 179:398-413
132. Unger WW, Pearson T, Abreu JR, Laban S, van der Slik AR, et al. 2012. Islet-specific CTL cloned from a type 1 diabetes patient cause β-cell destruction after engraftment into HLA-A2 transgenic NOD/SCID/IL2RG null mice. PLOS ONE 7:e49213
133. GallagherGR, BrehmMA, Finberg RW, Barton BA, Shultz LD, et al. 2015. Viral infection of engrafted human islets leads to diabetes. Diabetes 64:1358-69
134. Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, et al. 2014. Generation of functional human pancreatic βcells in vitro. Cell 159:428-39
135. Zhao T, ZhangZN, Westenskow PD,TodorovaD,HuZ, et al. 2015. Humanizedmice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell 17:353-59
136. Andrade D, Redecha PB, Vukelic M, Qing X, Perino G, et al. 2011. Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/-IL-2Rγ-/-mice: a promising model for studying human disease. Arthritis Rheumatol. 63:2764-73
137. RatliffML, Ward JM,Merrill JT, James JA, Webb CF. 2015. Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J. Immunol. 194:940-49
138. Kuwana Y, TakeiM, YajimaM, Imadome K, Inomata H, et al. 2011. Epstein-Barr virus induces erosive arthritis in humanized mice. PLOS ONE 6:e26630
139. Misharin AV, Haines GK, Rose S, Gierut AK, Hotchkiss RS, Perlman H. 2012. Development of a new humanized mouse model to study acute inflammatory arthritis. J. Transl. Med. 10:190
140. NolteT, Zadeh-Khorasani M, SafarovO, Rueff F, Gulberg V, et al. 2013. Oxazolone and ethanol induce colitis in non-obese diabetic-severe combined immunodeficiency interleukin-2Rγnull mice engrafted with human peripheral blood mononuclear cells. Clin. Exp. Immunol. 172:349-62
141. EschbornM,Weigmann B, Reissig S,Waisman A, Saloga J, Bellinghausen I. 2015. Activated glycoprotein A repetitions predominant (GARP)-expressing regulatoryTcells inhibit allergen-induced intestinal inflammation in humanized mice. J. Allergy Clin. Immunol. 136:159-68
142. Martin H, Reuter S, Dehzad N, Heinz A, Bellinghausen I, et al. 2012. CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J. Allergy Clin. Immunol. 129:521-528.E7
143. Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, et al. 2013. Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J. Immunol. 191:2890-99
144. Bryce PJ, Falahati R, Kenney L, Leung J, Bebbington C, et al. 2016. Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis. J. Allergy Clin. Immunol. 138:769-79
145. Goettel JA, Biswas S, Lexmond WS, Yeste A, Passerini L, et al. 2015. Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood 125:3886-95
146. Tezuka K, Xun R, Tei M, Ueno T, Tanaka M, et al. 2014. An animal model of adult T-cell leukemia: humanized mice with HTLV-1-specific immunity. Blood 123:346-55
147. Melican K, Aubey F, Dumenil G. 2014. Humanized mouse model to study bacterial infections targeting the microvasculature. J. Vis. Exp. 2014:51134
148. Kwant-Mitchell A, Ashkar AA, Rosenthal KL. 2009. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J. Virol. 83:10664-76
149. Tanner A, Carlson SA, Nukui M, Murphy EA, Berges BK. 2013. Human herpesvirus 6A infection and immunopathogenesis in humanized Rag2-/-γc-/-mice. J. Virol. 87:12020-28
150. Hakki M, Goldman DC, Streblow DN, Hamlin KL, Krekylwich CN, et al. 2014. HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMVseropositive donors. Biol. Blood Marrow Transplant. 20:132-35
151. Tan CS, Broge TA Jr., Seung E, Vrbanac V, Viscidi R, et al. 2013. Detection of JC virus-specific immune responses in a novel humanized mouse model. PLOS ONE 8:e64313
152. Wege AK, Florian C, Ernst W, Zimara N, Schleicher U, et al. 2012. Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response. PLOS Negl. Trop. Dis. 6:e1741
153. Arvin AM, Moffat JF, SommerM, Oliver S, Che X, et al. 2010. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr. Top. Microbiol. Immunol. 342:189-209
154. Valbuena G, Halliday H, Borisevich V, Goez Y, Rockx B. 2014. A human lung xenograft mouse model of Nipah virus infection. PLOS Pathog. 10:e1004063
155. Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, et al. 2015. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 348:aaa8205